PBMs negotiate drug prices and rebates with manufacturers for their employer and health plan customers. A Novo Nordisk ...

By capping the cost of Insulin, the drug companies are now off the hook for hundreds of millions of dollars owed in state Medicaid rebates, based on the new rebate structure in the ARP ...

And that problem is not unique to insulin. PBMs demand rebates and other payments from pharmaceutical companies as a condition of favorable placement for a medicine on the formulary, or list of ...

In its complaint, the FTC alleges that PBMs followed a “chase-the-rebate strategy,” which led to soaring insulin list prices and made it harder for Americans to get the crucial medication ...

Well, the way the system works, the higher the rebate, the more favorable the listing in terms of insulin and other drugs covered by insurance. The more favorable the listing or formularies ...

Improving the Patient Financial Experience Throughout the Patient Journey While many healthcare providers believe that improving the patient financial experience is a critical step for their ...

The drug gatekeepers favored versions of insulin with higher upfront prices and bigger rebate payments from pharmaceutical companies, which shifted more costs onto patients, the FTC alleged.

INSULIN LITIGATION DEEP-DIVE — As Congress ... The counties say their contracts require that rebates the PBMs negotiate with manufacturers must “pass through” to them, which payers can ...

Some diabetes patients this year have had trouble finding their preferred insulin brands as major drug manufacturers reported shortages of the medicine. USA TODAY set out to find out what patients ...

The Federal Trade Commission took action Friday against the nation’s three largest pharmacy benefit managers, accusing the ...

The US Federal Trade Commission sued units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. on Friday, accusing the drug middlemen of engaging in illegal rebate programs that drove up the ...